Nasdaq-listed biotechnology firm Windtree Therapeutics has secured two funding agreements totaling $520 million, with 99% of the proceeds earmarked for purchasing Binance Coin (BNB). The agreements include a $500 million equity line of credit (ELOC) and a $20 million stock purchase deal with Build and Build Corp. However, utilization of the ELOC requires shareholder approval to increase the company's authorized shares.
CEO Jed Latkin emphasized the strategic importance, stating: "Pending stockholder approval, the opportunity to secure additional funds for purchasing more BNB cryptocurrency is essential to our strategy." This follows Windtree's earlier July 2025 announcement of a $60 million BNB purchase plan, bringing its total committed BNB funding to nearly $700 million. Concurrently, Windtree partnered with Kraken for custody, trading, and OTC services to manage its growing BNB reserves.
The news boosted Windtree's stock (WINT) by 4.87%, continuing a 537.5% six-month surge. BNB traded at $761.12 at press time, down 0.15% amid a broader 17.5% monthly gain that included an all-time high on July 23. The move aligns with a trend of institutional BNB adoption, exemplified by Nano Labs' recent $90 million treasury expansion.